UBS Group
INO icon

UBS Group’s Inovio Pharmaceuticals INO Stock Holding History

UBS Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-83
Closed -$8K – 8661
2015
Q1 		$8K Sell
83
-75
-47% -$7.27K ﹤0.01% 7812
2014
Q4 		$17K Buy
+158
New +$19.3K ﹤0.01% 7878

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group's INO Position: Q2 2026 in Review

UBS Group increased its Inovio Pharmaceuticals (INO) stake by 5.1% in Q2 2026, buying an estimated $15K and bringing the position to 262,320 shares worth $289K. The position accounts for ﹤0.01% of the portfolio, ranked #6578.

UBS Group first reported a position in INO in Q4 2014 and has held it in 47 quarters since. The position peaked at $5.89M in Q1 2022. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • UBS Group held 262,320 shares of Inovio Pharmaceuticals worth $289K as of Q2 2026.
  • UBS Group bought 12,670 Inovio Pharmaceuticals shares in Q2 2026, an estimated $15K.
  • Inovio Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6578 holding.
  • UBS Group first reported a position in Inovio Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Inovio Pharmaceuticals position peaked at $5.89M in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.